# Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation

> **NCT07626281** · PHASE1 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 152 (estimated)

## Conditions studied

- Inclisiran Formulation

## Interventions

- **DRUG:** Inclisiran formulation containing PS80
- **DRUG:** Currently marketed inclisiran formulation

## Key facts

- **NCT ID:** NCT07626281
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-09
- **Primary completion:** 2026-12-21
- **Final completion:** 2026-12-21
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07626281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07626281, "Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07626281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*